These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 11566623)

  • 1. Effects of interleukin-2 therapy on the proliferation and differentiation of CD4/CD25 positive and CD4/CD25 negative cells in HIV+ patients.
    Caggiari L; Zanussi S; D'Andrea M; Bortolin MT; Crepaldi C; Caffau C; Paoli PD
    Eur Cytokine Netw; 2001; 12(3):430-6. PubMed ID: 11566623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, double-blinded, placebo-controlled trial of intermittent administration of interleukin-2 and prednisone in subjects infected with human immunodeficiency virus.
    Tavel JA; Sereti I; Walker RE; Hahn B; Kovacs JA; Jagannatha S; Davey RT; Falloon J; Polis MA; Masur H; Metcalf JA; Stevens R; Rupert A; Baseler M; Lane HC
    J Infect Dis; 2003 Aug; 188(4):531-6. PubMed ID: 12898439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effects of intermittent interleukin 2 therapy in patients with HIV infection: characterization of a novel subset of CD4(+)/CD25(+) T cells.
    Sereti I; Martinez-Wilson H; Metcalf JA; Baseler MW; Hallahan CW; Hahn B; Hengel RL; Davey RT; Kovacs JA; Lane HC
    Blood; 2002 Sep; 100(6):2159-67. PubMed ID: 12200381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-2 induced immune effects in human immunodeficiency virus-infected patients receiving intermittent interleukin-2 immunotherapy.
    Kovacs JA; Vogel S; Metcalf JA; Baseler M; Stevens R; Adelsberger J; Lempicki R; Hengel RL; Sereti I; Lambert L; Dewar RL; Davey RT; Walker RE; Falloon J; Polis MA; Masur H; Lane HC
    Eur J Immunol; 2001 May; 31(5):1351-60. PubMed ID: 11465092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between the degree of immune activation, production of IL-2 and FOXP3 expression in CD4+CD25+ T regulatory cells in HIV-1 infected persons under HAART.
    Terzieva V; Popova D; Kicheva M; Todorova Y; Markova R; Martinova F; Elenkov I; Yankova M
    Int Immunopharmacol; 2009 Jul; 9(7-8):831-6. PubMed ID: 19303058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of subcutaneous interleukin-2 therapy on CD4 subsets and in vitro cytokine production in HIV+ subjects.
    De Paoli P; Zanussi S; Simonelli C; Bortolin MT; D'Andrea M; Crepaldi C; Talamini R; Comar M; Giacca M; Tirelli U
    J Clin Invest; 1997 Dec; 100(11):2737-43. PubMed ID: 9389737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL-2 increased RANTES production and CD25 expression in cultured PBMCs only from antiretroviral treated HIV-1+ patients with detectable viral loads.
    Lozano JM; Kindelán JM; Cabello A; Gonzalez R; Solana R; Peña J
    Int Immunopharmacol; 2006 Jun; 6(6):1034-8. PubMed ID: 16644491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-10-secreting CD4 cells from aged patients with AIDS decrease in-vitro HIV replication and tumour necrosis factor alpha production.
    Andrade RM; Lima PG; Filho RG; Hygino J; Milczanowski SF; Andrade AF; Lauria C; Brindeiro R; Tanuri A; Bento CA
    AIDS; 2007 Aug; 21(13):1763-70. PubMed ID: 17690575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunophenotype of HIV+ patients during CD4 cell-monitored treatment interruption: role of the IL-7/IL-7 receptor system.
    Nemes E; Lugli E; Nasi M; Ferraresi R; Pinti M; Bugarini R; Borghi V; Prati F; Esposito R; Cossarizza A; Mussini C
    AIDS; 2006 Oct; 20(16):2021-32. PubMed ID: 17053348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic activation of CD4+ T cells by IL-16 and IL-2.
    Parada NA; Center DM; Kornfeld H; Rodriguez WL; Cook J; Vallen M; Cruikshank WW
    J Immunol; 1998 Mar; 160(5):2115-20. PubMed ID: 9498748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interruption of antiretroviral therapy blunts but does not abrogate CD4 T-cell responses to interleukin-2 administration in HIV infected patients.
    Keh CE; Shen JM; Hahn B; Hallahan CW; Rehm CA; Thaker V; Wynne SM; Davey RT; Lane HC; Sereti I
    AIDS; 2006 Feb; 20(3):361-9. PubMed ID: 16439869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the frequency of interleukin (IL)-2-, interferon-gamma-, and IL-4-producing T cells in 2 diseases, human immunodeficiency virus types 1 and 2, with distinct clinical outcomes.
    Sousa AE; Chaves AF; Loureiro A; Victorino RM
    J Infect Dis; 2001 Sep; 184(5):552-9. PubMed ID: 11494161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential alterations of the CD4 and CD8 T cell subsets in HIV-infected patients on highly active antiretroviral therapy with low CD4 T cell restoration.
    Méndez-Lagares G; García-Pergañeda A; del Mar del Pozo-Balado M; Genebat M; Ruiz-Mateos E; García García M; Muñoz-Fernández MÁ; Pacheco YM; Leal M
    J Antimicrob Chemother; 2012 May; 67(5):1228-37. PubMed ID: 22287235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The number and function of circulating dendritic cells may limit effector memory CD4+ T-cell responses in HIV patients responding to antiretroviral therapy.
    Fernandez S; Stone SF; Price P; French MA
    Clin Immunol; 2008 Aug; 128(2):228-37. PubMed ID: 18511344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD8+ T cells in HIV disease exhibit cytokine receptor perturbation and poor T cell receptor activation but are responsive to gamma-chain cytokine-driven proliferation.
    Pahwa R; McCloskey TW; Aroniadis OC; Strbo N; Krishnan S; Pahwa S
    J Infect Dis; 2006 Mar; 193(6):879-87. PubMed ID: 16479523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased population of CD4(+)CD25(high), regulatory T cells with their higher apoptotic and proliferating status in peripheral blood of acute myeloid leukemia patients.
    Wang X; Zheng J; Liu J; Yao J; He Y; Li X; Yu J; Yang J; Liu Z; Huang S
    Eur J Haematol; 2005 Dec; 75(6):468-76. PubMed ID: 16313258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulatory T cells generated ex vivo as an approach for the therapy of autoimmune disease.
    Horwitz DA; Zheng SG; Gray JD; Wang JH; Ohtsuka K; Yamagiwa S
    Semin Immunol; 2004 Apr; 16(2):135-43. PubMed ID: 15036237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunological changes in peripheral blood and in lymphoid tissue after treatment of HIV-infected subjects with highly active anti-retroviral therapy (HAART) or HAART + IL-2.
    Zanussi S; Simonelli C; Bortolin MT; D'Andrea M; Crepaldi C; Vaccher E; Nasti G; Politi D; Barzan L; Tirelli U; De Paoli P
    Clin Exp Immunol; 1999 Jun; 116(3):486-92. PubMed ID: 10361239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinetics of the changes of lymphocyte subsets defined by cytokine production at single cell level during highly active antiretroviral therapy for HIV-1 infection.
    Sousa AE; Chaves AF; Doroana M; Antunes F; Victorino RM
    J Immunol; 1999 Mar; 162(6):3718-26. PubMed ID: 10092835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Normalized CD8+ but not CD4+ lymphocyte IL-2 expression is associated with early treatment with highly active antiretroviral therapy.
    Akerele T; Galatowicz G; Bunce C; Calder V; Lynn WA; Lightman S
    Clin Immunol; 2006 Nov; 121(2):191-7. PubMed ID: 16987710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.